S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"

Eledon Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELDN)

$1.14
-0.01 (-0.87%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.12
$1.16
50-Day Range
$1.12
$1.69
52-Week Range
$1.07
$3.70
Volume
38,488 shs
Average Volume
58,054 shs
Market Capitalization
$27.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
835.7% Upside
$10.67 Price Target
Short Interest
Healthy
0.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Eledon Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($1.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

367th out of 952 stocks

Pharmaceutical Preparations Industry

163rd out of 445 stocks


ELDN stock logo

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock Price History

ELDN Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Eledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officer
See More Headlines
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+835.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-87,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.70 per share
Book Value
$3.77 per share

Miscellaneous

Free Float
19,504,000
Market Cap
$27.59 million
Optionable
Not Optionable
Beta
1.64
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. David-Alexandre C. Gros M.D.Dr. David-Alexandre C. Gros M.D. (Age 51)
    Ph.D., CEO & Non Independent Director
    Comp: $807.96k
  • Dr. Steven N. Perrin Ph.D. (Age 57)
    President, Chief Scientific Officer & Non Independent Director
    Comp: $603.9k
  • Mr. Paul Sean Little (Age 58)
    CFO & Principal Accounting Officer
    Comp: $611.71k
  • Mr. John Herberger
    Vice President of Technical Operations
  • Mr. Bryan E. Smith J.D. (Age 43)
    General Counsel, Corporate Secretary & Chief Compliance Officer
    Comp: $377.14k
  • Dr. David Hovland Ph.D.
    Chief Regulatory Officer
  • Dr. Eliezer Katz F.A.C.S.
    FACS, M.D., Chief Medical Officer














ELDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELDN shares.
View ELDN analyst ratings
or view top-rated stocks.

What is Eledon Pharmaceuticals' stock price target for 2024?

3 analysts have issued 1-year target prices for Eledon Pharmaceuticals' stock. Their ELDN share price targets range from $9.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next year. This suggests a possible upside of 835.7% from the stock's current price.
View analysts price targets for ELDN
or view top-rated stocks among Wall Street analysts.

How have ELDN shares performed in 2023?

Eledon Pharmaceuticals' stock was trading at $2.28 on January 1st, 2023. Since then, ELDN stock has decreased by 50.0% and is now trading at $1.14.
View the best growth stocks for 2023 here
.

Are investors shorting Eledon Pharmaceuticals?

Eledon Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 65,900 shares, an increase of 25.8% from the October 31st total of 52,400 shares. Based on an average daily volume of 88,800 shares, the short-interest ratio is presently 0.7 days.
View Eledon Pharmaceuticals' Short Interest
.

When is Eledon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ELDN earnings forecast
.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) posted its earnings results on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06.

Who are Eledon Pharmaceuticals' major shareholders?

Eledon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (7.54%), Jmac Enterprises LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little.
View institutional ownership trends
.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ELDN) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -